Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?

Parkinson's disease (PD) is a severe neurodegenerative disorder, with no available drugs able to prevent the neuronal cell loss characteristic in brains of patients suffering from PD. Due to the complex cascade of molecular events involved in the etiology of PD, an innovative approach towards neuroprotection or neurorescue may entail the use of multifunctional pharmaceuticals that target an array of pathological pathways, each of which is believed to contribute to events that ultimately lead to neuronal cell death. Here we discuss examples of novel multifunctional ligands that may have potential as neuroprotective and neurorestorative therapeutics in PD. The compounds discussed originate from synthetic chemistry as well as from natural sources where various moieties, identified in research to possess neuroprotective and neurorestorative properties, have been introduced into the structures of several monomodal drugs, some of which are used in the clinic.

[1]  Craig Mallinckrodt,et al.  Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. , 2002, The Journal of clinical psychiatry.

[2]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP‐induced striatal dopamine depletion , 2005, Journal of neurochemistry.

[3]  K. Lyseng-Williamson,et al.  Memantine , 2012, PharmacoEconomics.

[4]  M. Youdim,et al.  Neuroprotection via pro‐survival protein kinase C isoforms associated with Bcl‐2 family members , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  R. Duvoisin,et al.  Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. , 1985, European journal of pharmacology.

[6]  J. Bloomquist,et al.  Selective effects of cyclodiene insecticides on dopamine release in mammalian synaptosomes. , 2002, Toxicology and applied pharmacology.

[7]  W. Coetzee,et al.  Characterization of NGP 1-01, an aromatic polycyclic amine, as a calcium antagonist. , 1986, Pharmacological research communications.

[8]  R. Uitti,et al.  Familial Parkinson's Disease: Possible Role of Environmental Factors , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[9]  M. Piercey Pharmacology of Pramipexole, a Dopamine D3-Preferring Agonist Useful in Treating Parkinson's Disease , 1998, Clinical neuropharmacology.

[10]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[11]  B. Shukitt-Hale,et al.  Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. , 2005, The American journal of clinical nutrition.

[12]  Jack J. Chen,et al.  Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  D. Lahiri,et al.  Metal and inflammatory targets for Alzheimer's disease. , 2004, Current drug targets.

[14]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[15]  M. Youdim,et al.  Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. , 2005, Bioorganic & medicinal chemistry.

[16]  Wei Huang,et al.  Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[17]  P. Riederer,et al.  MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? , 2000, Parkinsonism & related disorders.

[18]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[19]  Piercey Mf Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. , 1998 .

[20]  M. Schwarzschild,et al.  Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. , 2003, Bioorganic & medicinal chemistry.

[21]  M. Naoi,et al.  (−)‐Deprenyl Protects Human Dopaminergic Neuroblastoma SH‐SY5Y Cells from Apoptosis Induced by Peroxynitrite and Nitric Oxide , 1998, Journal of neurochemistry.

[22]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[23]  W. Tatton,et al.  Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B , 2003, Journal of Neural Transmission.

[24]  C. J. Van der Schyf,et al.  Monoamine oxidase B inhibition and neuroprotection , 2003, Neurology.

[25]  Q. Guo,et al.  Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. , 1996, Biochimica et biophysica acta.

[26]  W. Geldenhuys,et al.  Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases , 2006, Expert opinion on investigational drugs.

[27]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[28]  J. Saura,et al.  Differential age-related changes of mao-a and mao-b in mouse brain and pe peripheral organs , 1994, Neurobiology of Aging.

[29]  Jack J. Chen,et al.  Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease , 2005, Journal of clinical pharmacology.

[30]  W. Geldenhuys,et al.  Screening of novel pentacyclo-undecylamines for neuroprotective activity. , 2003, European journal of pharmacology.

[31]  S. Mandel,et al.  Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. , 2006, Molecular nutrition & food research.

[32]  G. Lescoat,et al.  Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. , 1993, Biochemical pharmacology.

[33]  A. Korczyn,et al.  Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[34]  R. Hider,et al.  Metal chelation of polyphenols. , 2001, Methods in enzymology.

[35]  J. Friedman,et al.  Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients , 2004, Movement disorders : official journal of the Movement Disorder Society.

[36]  M. Youdim,et al.  Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases , 2005, Mechanisms of Ageing and Development.

[37]  M. Rogawski,et al.  The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. , 2006, CNS drug reviews.

[38]  M. Youdim,et al.  Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression , 2002, Psychopharmacology.

[39]  J. Saura,et al.  Biphasic and Region-Specific MAO-B Response to Aging in Normal Human Brain , 1997, Neurobiology of Aging.

[40]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[41]  R. Hider,et al.  Metal Chelation of Polyphenols , 2001 .

[42]  S. Mandel,et al.  Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives , 2005, Brain Research Reviews.

[43]  J. Hartmann,et al.  NGP1-01 is a Brain-permeable Dual Blocker of Neuronal Voltage- and Ligand-operated Calcium Channels , 2006, Neurochemical Research.

[44]  R. Prediger,et al.  Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats Involvement of adenosine A1 and A2A receptors , 2005, Neurobiology of Aging.

[45]  Neal Castagnoli,et al.  8-(3-Chlorostyryl)caffeine May Attenuate MPTP Neurotoxicity through Dual Actions of Monoamine Oxidase Inhibition and A2A Receptor Antagonism* , 2002, The Journal of Biological Chemistry.

[46]  M. Merello,et al.  Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.

[47]  A. de Mendonça,et al.  Does caffeine intake protect from Alzheimer's disease? , 2002, European journal of neurology.

[48]  M. Youdim,et al.  Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats , 2004, Neuropharmacology.

[49]  J. Connor,et al.  Iron, brain ageing and neurodegenerative disorders , 2004, Nature Reviews Neuroscience.

[50]  W. Geldenhuys,et al.  Multifunctional neuroprotective drugs for the treatment of cognitive and movement impairment disorders, including Alzheimer's and Parkinson's diseases , 2006 .

[51]  S. Mandel,et al.  Reduction of iron‐regulated amyloid precursor protein and β‐amyloid peptide by (–)‐epigallocatechin‐3‐gallate in cell cultures: implications for iron chelation in Alzheimer's disease , 2006, Journal of neurochemistry.

[52]  Nir Giladi,et al.  Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa , 2000, Clinical neuropharmacology.

[53]  M. Ikeda,et al.  Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. , 1995, The Journal of pharmacology and experimental therapeutics.

[54]  Richard Morphy,et al.  Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .

[55]  B. Schoenberg Environmental Risk Factors for Parkinson's Disease: The Epidemiologic Evidence , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[56]  T. Amit,et al.  Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro , 2007, Journal of neurochemistry.

[57]  S. Mandel,et al.  Neuroprotection and neurorescue against Aβ toxicity and PKC‐dependent release of non‐amyloidogenic soluble precursor protein by green tea polyphenol (‐)‐epigallocatechin‐3‐gallate , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  M. Youdim,et al.  The FASEB Journal express article 10.1096/fj.05-3794fje. Published online September 7, 2005. , 2022 .

[59]  F. Gonzalez,et al.  Parkinson's disease, pesticides and individual vulnerability. , 2004, Trends in pharmacological sciences.

[60]  Y. Agid,et al.  Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess®/Comtan® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment , 2005, European Neurology.

[61]  P. Jenner,et al.  Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. , 2002, European journal of pharmacology.

[62]  C. Olanow Neuroprotective Strategies in Parkinson’s Disease , 2009 .

[63]  J. Langston,et al.  Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. , 2004, Archives of neurology.

[64]  M. Youdim,et al.  Attenuation of MPTP‐induced dopaminergic neurotoxicity by TV3326, a cholinesterase‐monoamine oxidase inhibitor , 2003, Journal of neurochemistry.

[65]  Fabrizio Gardoni,et al.  New targets for pharmacological intervention in the glutamatergic synapse. , 2006, European journal of pharmacology.

[66]  David Morgan,et al.  Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice , 2005, The Journal of Neuroscience.

[67]  M. Youdim,et al.  Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B , 2001, British journal of pharmacology.

[68]  W. Geldenhuys,et al.  Synthesis and biological evaluation of pentacyclo[5.4.0.02,6.03,10.05,9]undecane derivatives as potential therapeutic agents in Parkinson's disease , 2004 .

[69]  M. Kaps,et al.  Neuroprotective effects of MK-801 in different rat stroke models for permanent middle cerebral artery occlusion: adverse effects of hypothalamic damage and strategies for its avoidance. , 2003, Stroke.

[70]  S. Mandel,et al.  Multifunctional Activities of Green Tea Catechins in Neuroprotection , 2005, Neurosignals.

[71]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.

[72]  M. Küçük,et al.  Reduction of Edema and Infarction by Memantine and MK-801 After Focal Cerebral Ischaemia and Reperfusion in Rat , 2000, Acta Neurochirurgica.

[73]  S. Starkman,et al.  Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke , 2003, Current treatment options in neurology.

[74]  M. Youdim,et al.  Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness , 2006, British journal of pharmacology.

[75]  M. Youdim The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. , 2006, Current Alzheimer research.

[76]  W. Geldenhuys,et al.  NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia , 2005, Neuroscience Letters.

[77]  A. Markham,et al.  Pramipexole. A review of its use in the management of early and advanced Parkinson's disease. , 1998, Drugs & aging.

[78]  E. Hall,et al.  Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons , 1996, Brain Research.

[79]  T. Amit,et al.  The neuroprotective effect of Activin A and B: implication for neurodegenerative diseases , 2007, Journal of neurochemistry.

[80]  D. Souza,et al.  Neuroprotection by caffeine and adenosine A2A receptor blockade of β‐amyloid neurotoxicity , 2003, British journal of pharmacology.

[81]  C. Olanow,et al.  Neuroprotection in Parkinson's disease: Clinical trials , 2003, Annals of neurology.

[82]  T. Odergren,et al.  Animal models of stroke: do they have value for discovering neuroprotective agents? , 2003, Trends in pharmacological sciences.

[83]  W. Tatton,et al.  (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. , 1996, Journal of neural transmission. Supplementum.

[84]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[85]  M. Naoi,et al.  N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2 , 2005, Journal of Neural Transmission.

[86]  B. Szende,et al.  (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. , 2004, Neurotoxicology.

[87]  S. Mandel,et al.  Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. , 2004, The Journal of nutritional biochemistry.

[88]  P. Riederer,et al.  Monoamine oxidase-B inhibition in Alzheimer's disease. , 2004, Neurotoxicology.

[89]  M. Youdim,et al.  Novel Neuroprotective Mechanism of Action of Rasagiline Is Associated with Its Propargyl Moiety: Interaction of Bcl‐2 Family Members with PKC Pathway , 2005, Annals of the New York Academy of Sciences.

[90]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[91]  F. Crews,et al.  TNFα potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NFκB inhibition , 2005, Brain Research.

[92]  D. Wong,et al.  LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. , 1988, Life sciences.

[93]  M. Youdim,et al.  Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease 1 , 2007, Journal of neurochemistry.

[94]  W. Geldenhuys,et al.  Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor. , 2007, Bioorganic & medicinal chemistry.

[95]  J. Buccafusco,et al.  CNS Targets for multi-functional drugs in the treatment of Alzheimer’s and Parkinson’s diseases , 2005, Journal of Neural Transmission.

[96]  E. Bézard,et al.  Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. , 2004, Trends in pharmacological sciences.

[97]  R. Levy,et al.  Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor , 2004, Pharmacotherapy.

[98]  J. Kemp,et al.  NMDA receptor pathways as drug targets , 2002, Nature Neuroscience.

[99]  N. Cutler,et al.  Recent Developments in the Drug Treatment of Alzheimer’s Disease , 1999, Drugs & aging.

[100]  S. Gullans,et al.  Drug discovery targeted to the Alzheimer’s APP mRNA 5′-untranslated region , 2007, Journal of Molecular Neuroscience.

[101]  B. Szende,et al.  Pharmacological aspects of (-)-deprenyl. , 2004, Current medicinal chemistry.

[102]  M. Chevion,et al.  Protective effects of tea polyphenols against oxidative damage to red blood cells. , 1997, Biochemical pharmacology.

[103]  Andrea Mattevi,et al.  Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[104]  J. Jankovic,et al.  Prevention and restoration of lactacystin‐induced nigrostriatal dopamine neuron degeneration by novel brain‐permeable iron chelators , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[105]  S. Mandel,et al.  Green tea polyphenol (–)‐epigallocatechin‐3‐gallate induces neurorescue of long‐term serum‐deprived PC12 cells and promotes neurite outgrowth , 2005, Journal of neurochemistry.

[106]  P. Riederer,et al.  Selegiline is neuroprotective in primary brain cultures treated with 1-methyl-4-phenylpyridinium. , 1996, European journal of pharmacology.

[107]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[108]  T. Suuronen,et al.  Protective effect of L-deprenyl against apoptosis induced by okadaic acid in cultured neuronal cells. , 2000, Biochemical pharmacology.

[109]  M. Youdim,et al.  Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition , 2005, Journal of neuroscience research.

[110]  M. Tabata,et al.  Effects of pH and Metal Ions on Antioxidative Activities of Catechins , 2001, Bioscience, biotechnology, and biochemistry.

[111]  S. Mandel,et al.  Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism , 2007, Neurobiology of Disease.

[112]  K. Perry,et al.  Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. , 1988, The Journal of pharmacology and experimental therapeutics.

[113]  M. Limburg,et al.  Calcium antagonists for acute ischemic stroke. , 2000, The Cochrane database of systematic reviews.

[114]  M. Youdim,et al.  Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition , 2005, Journal of neurochemistry.

[115]  A. Siderowf,et al.  A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.

[116]  P. Lipton,et al.  Ischemic cell death in brain neurons. , 1999, Physiological reviews.